Skip to main navigation Skip to search Skip to main content

Ototoxicity and cochlear sparing in children with medulloblastoma: Proton vs. photon radiotherapy

  • Arnold C. Paulino
  • , Anita Mahajan
  • , Rong Ye
  • , David R. Grosshans
  • , M. Fatih Okcu
  • , Jack Su
  • , Mary Frances McAleer
  • , Susan McGovern
  • , Victor A. Mangona
  • , Murali Chintagumpala

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To compare ototoxicity rates between medulloblastoma patients treated with protons vs. photons. Materials and methods: The study included 84 children diagnosed with medulloblastoma treated with either passively scattered protons (n = 38) or photons (n = 46). Patients underwent maximal safe resection followed by craniospinal irradiation, posterior fossa and/or tumor bed boost and chemotherapy according to one of 3 multi-institutional trials. Median audiogram follow-up was 56 months for protons and 66 months for photons. Results: Mean cochlear dose (Dmc) was lower in patients treated with protons for both standard (p < 0.0001) and high-risk disease (p < 0.001). Grade 3 and 4 ototoxicity was seen in 7 of 75 (9.3%) and 9 of 91 (9.9%) ears (Brock, p = 0.91), 13 of 75 (17.3%) and 19 of 91 (20.9%) ears (POG, p = 0.56), and 15 of 75 (20.0%) and 21 of 91 (23.1%) ears (SIOP Boston, p = 0.63) with protons and photons respectively. Conclusions: While cochlear doses were lower in the proton group, patients treated with either protons or photons had similar Grade 3 and 4 ototoxicity rates.

Original languageEnglish (US)
Pages (from-to)128-132
Number of pages5
JournalRadiotherapy and Oncology
Volume128
Issue number1
DOIs
StatePublished - Jul 2018
Externally publishedYes

Keywords

  • Intensity modulated radiation therapy
  • Medulloblastoma
  • Ototoxicity
  • Proton therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint

Dive into the research topics of 'Ototoxicity and cochlear sparing in children with medulloblastoma: Proton vs. photon radiotherapy'. Together they form a unique fingerprint.

Cite this